NOTICE 1 페이지

NEWS & EVENT

Total 10 - 1 page

No	Subject	Date	Hit
10	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	1,157
익명 1,157 2021.07.15
9	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	949
익명 949 2022.11.09
8	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	1,494
익명 1,494 2024.02.27
7	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	1,109
익명 1,109 2024.05.21
6	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	1,093
익명 1,093 2024.07.10
5	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	1,310
익명 1,310 2024.10.07
4	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	755
익명 755 2024.11.21
3	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	792
익명 792 2025.02.13
2	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	533
익명 533 2025.03.31
1	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	133
익명 133 2025.06.14

INVESTORS & MEDIA